Imatinib binds the ATP site of ABL1/BCR‑ABL, blocking autophosphorylation and downstream MAPK/PI3K‑AKT survival signaling, leading to cell‑cycle arrest and apoptosis in ABL‑dependent (e.g., BCR‑ABL+) cells.